BioTelemetry, Inc. (NASDAQ:BEAT) is scheduled to be releasing its earnings data on Tuesday, November 7th. Analysts expect BioTelemetry to post earnings of $0.25 per share for the quarter.

BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings results on Tuesday, August 8th. The medical research company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.02. The business had revenue of $58.10 million during the quarter, compared to the consensus estimate of $58.39 million. BioTelemetry had a net margin of 21.03% and a return on equity of 18.75%. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.20 earnings per share. On average, analysts expect BioTelemetry to post $0.95 EPS for the current fiscal year and $1.30 EPS for the next fiscal year.

BioTelemetry, Inc. (NASDAQ BEAT) traded up 1.40% during mid-day trading on Tuesday, reaching $29.05. 434,735 shares of the company’s stock traded hands. BioTelemetry, Inc. has a 12-month low of $15.25 and a 12-month high of $39.20. The stock has a market capitalization of $940.06 million, a PE ratio of 19.50 and a beta of 0.69. The stock has a 50-day moving average price of $32.30 and a 200-day moving average price of $32.34.

COPYRIGHT VIOLATION NOTICE: “BioTelemetry, Inc. (BEAT) Scheduled to Post Earnings on Tuesday” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at

Several research firms have commented on BEAT. BidaskClub lowered shares of BioTelemetry from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Sidoti reiterated a “buy” rating and set a $49.00 price objective (up previously from $42.00) on shares of BioTelemetry in a research report on Thursday, August 10th. Lake Street Capital restated a “buy” rating and issued a $50.00 target price (up previously from $35.00) on shares of BioTelemetry in a report on Friday, July 14th. Dougherty & Co raised their target price on shares of BioTelemetry from $37.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, August 9th. Finally, Zacks Investment Research upgraded shares of BioTelemetry from a “hold” rating to a “strong-buy” rating and set a $39.00 target price for the company in a report on Friday, August 11th. One analyst has rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $42.86.

BioTelemetry Company Profile

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Earnings History for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with's FREE daily email newsletter.